Jazz Pharmaceuticals plc (JAZZ)
JAZZNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$241.55
+1.18 (+0.49%) today
At the close, Nov 13, 4:00 PM ET. After hours $241.55 –
- Market cap
- $15.50bn
- P/E
- 21.4
- EPS, last 4 quarters
- $11.28
- Dividend yield
- –
- Day range
- $235.89 to $243.25
- 52-week range
- $136.56 to $266.38
- Average volume
- –
- Previous close
- $240.37
Analysts
17 coveringBuy16 buy, 1 hold, 0 sell
Targets a year out average $303.29, +25.6% from here
Earnings
next estimate $5.93Next report
Dec 2025
+1.9%
Mar 2026
+42.9%
Jun 2026
-3.4%
Sep 2026
+6.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $1.20bn | $1.07bn | $1.21bn | $1.24bn |
| Gross profit | $1.04bn | $934.80m | $1.09bn | $1.13bn |
| Operating income | $254.56m | $336.60m | $248.20m | -$413.40m |
| Net income | $203.45m | $293.10m | $192.80m | -$483.40m |
Last four quarters: revenue $4.72bn, margin 4.4%, free cash flow $1.62bn
News
8 latest- Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the StockZacks · 4 days ago
- JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales ViewZacks · Nov 3, 2026
- Jazz (JAZZ) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- Jazz Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
- Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · Nov 2, 2026
- Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineThe Motley Fool · Oct 27, 2026
- Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 27, 2026
The company
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- jazzpharmaceuticals.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.